An Open-Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Peginterferon beta-1a (Primary) ; Naproxen
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Acronyms ALLOW
- Sponsors Biogen
- 28 Apr 2017 Results of treatment satisfaction questionnaire for medication (n=194) presented at the 69th Annual Meeting of the American Academy of Neurology
- 04 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 01 Jun 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov